Background. Nisoldipine is a potent 1:4 dihydropyridine calcium channel antagonist, and doses of 5 or 10 mg administered either once or twice daily have been claimed to exert antianginal effects. There is, however, little information regarding the dose-response relation and whether the drug exerts any consistent effects throughout the dosing interval. In this placebo-controlled, parallel-design study, the dose-response relation of monotherapy with nisoldipine administered twice daily was studied in patients with stable angina pectoris.
Methods and Results. Two hundred thirty-one patients received single-blind placebo for 2 weeks; of these, 185 patients who reproducibly stopped treadmill exercise because of angina of moderate severity and had .1 mm ST segment depression during exercise and experienced an average of three episodes of anginal attacks per week were randomized in a double-blind manner to one of the four treatment groups: placebo (n=48), nisoldipine 2.5 mg (n=47), nisoldipine 5 mg (n=44), or nisoldipine 10 mg (n=46). Nisoldipine or placebo was administered twice daily for 4 weeks and symptom-limited exercise tests were repeated at 2 and 10-14 hours after the double-blind medication. One hundred sixty-eight patients completed the study and 181 patients were valid for efficacy analysis. Compared with double-blind placebo, there were marginally significant trends toward increases for time to onset of angina for the 10-mg-b.i.d. group (83 versus 108 seconds, p=0.08), time to 1 mm ST segment depression for the 5-mg-b.i.d. group (54 versus 83 seconds, p=0.08), and total exercise time for the 5-(30 versus 50 seconds, p=0.10) and 10-mg-b.i.d. (30 versus 58 seconds, p=0.06) groups at 2 hours after the dose (peak effect) after 4 weeks of therapy. At 10-14 hours after the dose (trough effect), no differences between placebo and any of the nisoldipine doses on any of the exercise parameters were found after 4 weeks of therapy. A subset analysis of patients who stopped exercise within 10 minutes because of angina of moderate severity during single-blind placebo therapy (n = 123) revealed significant increase in total exercise duration and time to 1 mm ST segment depression at 2 hours after the dose in the 5-and 10-mg-b.i.d. dose groups compared with double-blind placebo (p<0.04). No significant trough effects, however, were observed even in this subgroup after any of the doses of nisoldipine. The frequency of anginal attacks decreased by 44%, 41%, 30%, and 41% after twice-daily therapy with 2.5 mg, 5 mg, 10 mg nisoldipine, and placebo groups, respectively (p=NS, nisoldipine versus placebo). The incidence of adverse events (minor and major) was 43.8% in the placebo group and 42.6%o, 45.5%, and 56.5% in the nisoldipine 2.5-, 5-, and 10-mg-b.i.d. groups, respectively (p=NS compared with placebo). However, four patients developed unstable angina while on nisoldipine therapy (two in the 2.5-mg, one in the 5-mg, and one in the 10-mg-b.i.d. group) and two patients died suddenly in the nisoldipine 10-mg-b.i. The protocol described below is summarized in Figure 1 . After the screening visit (week 0) described above, patients who qualified for the study were given a placebo, one capsule twice a day at 8 AM and 8 PM, for 2 weeks in a single-blind manner. They kept a record of their activity, frequency of anginal attacks, and sublingual nitroglycerin tablets consumed. At the end of weeks 1 and 2, they reported to the laboratory in the morning but were asked not to take the dose of morning medication until after the visit. Symptomlimited treadmill exercise (modified Bruce) test was performed at the end of week 1 and 2 at 10-14 hours after the study medication taken the night before.
To qualify for the double-blind portion of the study, patients had to be at least 75-115% compliant with the study medication and had to have had at least an average of three episodes of angina per week during the 2-week single-blind period; in addition, their exercise duration at week 2 had to be within 25% of that at week 1. Patients who did not meet the reproducibility criteria were permitted to receive single-blind placebo for another week, and the exercise test was repeated at the end of 1 week. If the exercise duration at visit 3 was within 25% of the duration at week 2, they were allowed to enter the double-blind portion of the study; otherwise, they were dropped from the study.
Patients meeting the eligibility criteria entered the double-blind portion of the study and were randomly assigned to one of the four treatment groups (placebo, 2.5 mg, 5 mg, or 10 mg b.i.d. nisoldipine) for the next 4 weeks. They were asked to take the study medication at 8 AM and 8 PM and were seen at weekly intervals. At the end of 2 weeks of double-blind therapy, patients underwent an exercise test 10-14 hours after the evening dose taken the night before.
At the end of 4 weeks of double-blind therapy, an exercise test was performed 2 hours after the morning dose of the medication (peak effect) and a day later. 10-14 hours after the dose taken the night before (trough effect).
When the subjects completed the double-blind portion of the study, they had the option of entering the long-term study and were treated with open-labeled nisoldipine. Those who did not enter the long-term study had their former medication resumed.
Laboratory Measurements and Statistics
The usual precautions customary for antianginal trials were taken. Records of 12-lead electrocardiogram and cuff blood pressure at rest, during, and for 10 minutes after exercise testing were obtained, and average heart rate and ST segment depression were determined. The end point during exercise was angina of moderate severity during the screening and single-blind placebo therapy; during double-blind therapy, the treadmill test could be terminated for either angina of moderate severity or other end points such as fatigue, extreme shortness of breath, or ventricular arrhythmias.
Criteria for Effectiveness
The primary treadmill test variables were time to onset of angina, time to 1 mm ST segment depression, and total time on treadmill. Secondary efficacy measurements were time to maximum ST segment depression, maximum ST segment depression, occurrence of angina, and occurrence of 1 mm ST segment depression. Response was also assessed by functional improvement, which was measured by the number of angina attacks and the number of nitroglycerin tablets taken. Reductions of >50% in number of attacks ST4, ST segment depression; double product, heart rate x systolic blood pressure in mm Hg/minx 102.
or nitroglycerin tablet consumption were considered to be positive responses. Safety Evaluation All patients given double-blind drug with documented follow-up were included in the safety evaluation. Patients were observed and questioned at each visit about adverse experiences. The following tests were performed before and after the study: hematology, including complete blood count, platelet count, serum chemistry, and routine urinalysis. Chest x-rays were obtained at the beginning of the study if none had been available within the previous 6 months and at the conclusion of the study.
Statistical Analysis
All tests were conducted with a one-tailed a-level of 0.05. All analyses were conducted using the SAS package (SAS Institute, Cary, N.C.). Continuous response variables were ranked and transformed to inverse normal scores to enhance statistical efficiency. The inverse normal scores were analyzed for dependence on dose level with study center included as a blocking factor, using analysis of variance. Tests for trend, differences from placebo, and difference among active doses were formulated as contrasts in the within-dose group mean scores.
Discrete response variables (including differences from baseline) were analyzed for correlation with dose level using the Mantel-Haenszel test statistics with the marginal levels as scores. Pairwise comparisons among dose groups were conducted using Fisher's exact test.
Homogeneity of Centers
Because of wide variations in center sizes, centers having fewer than 12 patients were grouped successively in descending order by size based on the number of valid patients known before breaking the random code, with the centers having an identical number of valid patients treated as blocks. These center-group sizes were: 31, 18, 17, 16; (10, 10, 9), (7, 6, 6, 6, 6, 6) , and (3, 3, 2, 2, 2, 1, 1, 1, 1).
An analysis to determine treatment by center interaction was conducted for all treadmill test parameters and functional improvement measures. In addition, individual within-center tests for trend, a center-adjusted test for trend (along with the pooled test for trend), and a test for variability in the within-center trends were also conducted.
Results

Patient Population
Two hundred thirty-one patients entered the study and received single-blind placebo therapy. Forty-six of the 231 patients did not enter the double-blind phase of the study for the following reasons: 21 patients did not meet the exercise reproducibility criteria, eight patients did not have sufficient episodes of anginal attacks, five patients experienced increased angina, four patients developed concomitant disease, two patients refused to enter, and one patient had transportation problems. There were protocol violations in two patients, and three patients experienced adverse effects and chose to discontinue participation. Thus, 185 patients were randomized to twice-daily therapy with either placebo, 2.5 mg, 5 mg, or 10 mg nisoldipine. Their baseline characteristics are shown in Table 1 . The demographic data (Table  1) were similar for the four groups.
Of the 185 patients, 168 patients completed the study. The reasons for withdrawal from the study were: adverse experience (nine patients), lack of effect of therapy (five patients), lost to follow-up (one patient), patient chose to withdraw (one patient), and protocol violation (one patient). (Figure 2) . The double product at termination of exercise did not change significantly from baseline values after either placebo or nisoldipine therapy (Table 3) .
Subgroup Analysis
Because the beneficial effects of Figure 3 ). There was also no significant improvement in any group over placebo for 50% reduction in angina attacks or nitroglycerin consumption ( Adverse Effects All patients given active drug with documented follow-up were included in the safety evaluation. Twenty-one of the 48 patients (43.8%) in the placebo group, 20 of 47 patients (42.6%) in the 2.5-mg-b.i.d. nisoldipine group, 20 of 44 patients (45.5%) in the 5-mg-b.i.d. nisoldipine group, and 26 of 46 patients (56.5%) in the 10-mg-b.i.d. nisoldipine group experienced adverse experiences. Headache was the most frequent complaint in the placebo group, dizziness in the 2.5-mg and 5-mg groups, and headache in the 10-mg-b.i.d. group. Digestive symptoms were common in all groups. There were two deaths in the 10-mg group; one resulted from ventricular fibrillation and the other from cardiac arrest. Seven patients were dropped from the study due to adverse experiences; two in the placebo group due to headaches and dizziness, two in the 2.5-mg-b.i.d. group due to unstable angina, one in the 5-mg-b.i.d. group due to unstable angina, and two in the 10-mg-b.i.d. group (one due to unstable angina and one due to dizziness). Nine other patients discontinued therapy because of an increase in frequency of angina (n=5; one in placebo group, two in the 2.5-mg-b.i.d. group, one in 5-mg-b.i.d. group, and one in 10-mg-b.i.d. group) or for other reasons (n=4) unrelated to the study drug. A rise in the occurrence of adverse events with increasing dose relative to baseline achieved statistical significance (p <0.05) after 4 weeks on study medication. The 10-mg-dose group had marginally (p<0.10) more severe adverse events than the placebo group. The clinical characteristics of two patients who died and four patients who developed unstable angina during nisoldipine therapy were not different from patients who did not experience serious adverse events during double-blind therapy.
Discussion
This multicenter study was carried out to evaluate the usefulness of twice-daily therapy with three different doses of nisoldipine in patients with stable angina pectoris. There was a marginally significant increase in total exercise duration and reduction in myocardial ischemia at 2 hours after the dose after 4 weeks of twice-daily therapy with 5 and 10 mg nisoldipine. None of the doses, however, exerted any beneficial trough effects at 10-14 hours after the dose on any exercise parameters. The frequency of anginal attacks decreased by a similar magnitude during placebo and nisoldipine therapy. The rate-pressure product at the termination of exercise did not change after either the placebo or any of the doses of nisoldipine compared with respective baseline values.
The criteria for entry in the study were not as stringent as in other studies. As long as patients stopped exercise because of angina of moderate severity, had 1 mm or greater ST segment depression during exercise while on single-blind placebo therapy, and had at least an average of three episodes of anginal attacks per week during 2 weeks of placebo therapy, they were entered in the double-blind portion of the study. Further, the reproducibility criteria during two exercise tests for the total exercise duration during the single-blind placebo therapy was 25%. Nonetheless, the patients enrolled in this study are representative of patients experiencing angina pectoris in the outpatient setting. When a post hoc analysis in the subgroup of patients with greater limitation of exercise at baseline (i.e., those patients who stopped exercise by 10 minutes because of angina of moderate severity) was performed, a significant improvement in total exercise duration and time to 1 mm ST segment depression was seen in the 5-and 10-mg-b.i.d. groups at 2 hours after the dose.
No trough effects could be demonstrated for any of the doses of nisoldipine, a finding similar to that observed for the entire group. Importantly, even in this subgroup, double-blind, placebo-adjusted increase in total exercise duration at 2 hours after the dose was only 22 seconds in the 5 -mg-b.i.d. group and 38 seconds in the 10-mg-b.i.d. group, values of marginal clinical significance.
Differences in the study design may explain the discrepancy between the results of the present study and of previously published reports. In an earlier crossover study, in a smaller number of patients (n = 12), effects of single doses of 5, 10, and 20 mg nisoldipine were evaluated at 1, 3, and 8 hours after the dose was given.1' After 10-and 20-mg doses, significant increase in total exercise duration was present at 1 hour after the dose and was maximal at 3 hours after the dose. At 8 hours after the dose, total exercise duration increased after the 10-and 20-mg doses but achieved statistical significance only after the 20-mg dose. The improvement in exercise duration at 3 hours after the dose was greater in that study compared with the improvement in exercise tolerance at 2 hours after the dose in the present investigation. In the present study, the average group values of total exercise duration at baseline during single-blind therapy in patients assigned to placebo and three different doses of nisoldipine are comparable with those reported by Lam et al"l in their patients during double-blind placebo therapy. In the present study, at 2 hours after the dose, there was an increase of 53 seconds in total exercise duration from baseline values after double-blind placebo therapy. We believe this accounted for the difference in results observed in the present study from those reported by Lam et al, who did not study the effects of chronic placebo therapy. In two other positive reports, effects of 2.5, 5, and 10 mg nisoldipine prescribed twice daily were compared with baseline single-blind therapy period and open-label placebo therapy at the end of active treatment.13"14 In these studies, the doses of nisoldipine were not randomly administered (the 5-mg dose was given before the 10-mg dose), nor was there a parallel placebo group, nor a placebo administered in a double-blind manner.
The trough effects (10-14 hours after the dose was given) of nisoldipine during chronic twice-daily therapy evaluated in the present study have not been studied previously either during therapy with nisoldipine12-'4 or other currently available calcium channel blocking agents. Nifedipine, verapamil, and diltiazem were approved by the U.S. Food and Drug Administration on the basis of their peak effects rather than by documentation of efficacy throughout the dosing intervals. Anginal attacks and nitroglycerin consumption decreased by a similar magnitude after nisoldipine and placebo therapy, indicative that placebo has marked antianginal effects, a finding reported previously in similar parallel-design placebo-controlled studies. 16 One could argue that doses of nisoldipine 2.5-10 mg prescribed twice daily did not exert any antianginal or anti-ischemic effects at 10-14 hours after the dose because the trough plasma nisoldipine concentrations were probably low. Earlier studies suggest that plasma half-life of nisoldipine is only 2-9 hours.17 Using a more sensitive assay technique that permits detection of very low concentrations of nisoldipine and its metabolites, some of which are pharmacologically active, a plasma half-life of 15.4 hours has been reported. 17"18 In the present study, we did not measure blood nisoldipine concentrations. However, at rest, the 10-mg-b.i.d. dose exerted significant hemodynamic effects as evidenced by an average fall in systolic blood pressure of 16 mm Hg at 2 hours after the dose and of 12 mm Hg at 10-14 hours after the dose. The effects on exercise parameters in the 10-mg-b.i.d. group were, however, of marginal clinical significance even at 2 hours after the dose, a time point when plasma nisoldipine concentrations are near maximum over a wide range of doses.17
Because there was a trend toward an increase in exercise duration at 2 hours after the dose in the 10-mg-b.i.d. nisoldipine group (Figure 2) , one might speculate that higher doses would be beneficial.
However, we would recommend caution in evaluating doses higher than those used in the present study because of an increased incidence of unstable angina and sudden death in the nisoldipine-treated group compared with the placebo-treated group. Compared with respective baseline values, systolic blood pressure decreased significantly at 2 and 10-14 hours after the dose in the 10-mg-BID (twice daily) (*p<0.001) and in the 5-mg-BID groups (tp<0.05). Reduction in diastolic blood pressure was significant at 2 hours after the dose in the 10-mg-BID group (*p <0.001). The reduction in systolic bloodpressure in the 10-mg-BID dose group was significantly greater compared with placebo both at 2 and 10-14 hours after the dose (#p<0.001).
5-mg-b.i.d., and one in the 10-mg-b.i.d. group), and two patients died in the 10-mg-b.i.d. group. Furthermore, four of the five other patients who discontinued double-blind therapy because of an increase in angina were in the nisoldipine groups. There were no instances of unstable angina or death in the placebotreated group. The reason for development of unstable angina during therapy with nisoldipine was not clear but could have been due to a coronary steal secondary to potent vasodilatory effects of nisoldipine on the coronary vasculature. 19 The higher incidence of serious adverse events in the 10-mg-b.i.d. nisoldipine group compared with the placebo group achieved near statistical significance (p<0.10). The higher incidence of serious adverse events during nisoldipine therapy is of special concern as similar serious adverse events have been reported with other potent dihydropyridine calcium channel blockers, nifedipine and nicardipine. Worsening of angina caused by coronary steal in patients with stable angina2021 and increased incidence of myocardial infarction or death in patients with unstable angina2223 have been reported during nifedipine therapy. In 425 patients with stable angina, long-term therapy with nifedipine (average dose, 80 mg/day) was associated with an increased number of deaths (n = 12) compared with therapy with placebo (two deaths) over a 3-year follow-up period.24 Similarly, nicardipine therapy was associated with a higher incidence of myocardial infarction (n=14) compared with placebo therapy (n =8), which did not achieve statistical significance (p=0.27), over a 2-year follow-up period in 383 patients with coronary artery disease, 239 of whom had angina pectoris.25 In crossover studies in a smaller number of patients with stable angina pectoris, oral nicardipine compared with placebo therapy was associated with increased incidence, which did not reach statistical significance, of myocardial ischemic complications (myocardial infarction, unstable angina, or increased frequency of angina).26'27 Provocation of myocardial ischemia at rest after intravenous nicardipine has also been reported in a patient with stable angina pectoris caused by severe coronary artery disease.28 Considering these facts and reports that potent dihydropyridine calcium channel blockers are associated with increased mortality in post-myocardial infarction patients compared with the control or placebo-treated group,29 we feel that it would be unethical to evaluate the effects of higher doses of standard formulation of nisoldipine than that used in the present study. We would, however, like to point out that in the present study, we evaluated the effects of nisoldipine prescribed as monotherapy. It is possible that when given in combination with a l3-blocker, nisoldipine may exert beneficial antianginal effects.12 However, adequately designed studies in a larger number of patients are required to address this issue.
The results of the present study show that twice-daily monotherapy with 2.5-10 mg nisoldipine was not superior to placebo therapy in treating patients with angina pectoris and that the 10-mg-b.i.d. therapy resulted in a statistically insignificant but clinically important increase in the incidence of serious adverse events.
